FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2000330957> ?p ?o ?g. }

• W2000330957 endingPage "2128" @default.
• W2000330957 startingPage "2122" @default.
• W2000330957 abstract "An open-label randomised comparison of efficacy and tolerability of irinotecan plus high-dose 5-fluorouracil (5-FU) and leucovorin (LV) (ILF) with etoposide plus 5-FU/LV (ELF) in patients with untreated metastatic or locally advanced gastric cancer. One cycle of ILF comprised six once-weekly infusions of irinotecan 80 mg m−2, LV 500 mg m−2, 24-h 5-FU 2000 mg m−2, and ELF comprised three once-daily doses of etoposide 120 mg m−2, LV 300 mg m−2, 5-FU 500 mg m−2. In all, 56 patients received ILF and 58 ELF. Median age was 62 years, Karnofsky performance 90%, and disease status was comparable for both arms. The objective clinical response rates after 14 weeks treatment (primary end point) were 30% for ILF and 17% for ELF (risk ratio (RR) 0.57, 95% confidence interval (CI) 0.29–1.13, P=0.0766). Overall response rates over the entire treatment period for ILF and ELF were 43 and 24%, respectively (RR 0.56, 95% CI 0.33–0.97; P=0.0467). For ILF and ELF, respectively, median progression-free survival was 4.5 vs 2.3 months, time to treatment failure was 3.6 vs 2.2 months (P=0.4542), and overall survival was 10.8 vs 8.3 months (P=0.2818). Both regimens were well tolerated, the main grade 3/4 toxicities being diarrhoea (18%, ILF) and neutropenia (57%, ELF). The data from this randomised phase II study indicate that ILF provides a better response rate than ELF, and that ILF should be investigated further for the treatment of metastatic gastric cancer." @default.
• W2000330957 created "2016-06-24" @default.
• W2000330957 creator A5004381584 @default.
• W2000330957 creator A5009529288 @default.
• W2000330957 creator A5013949384 @default.
• W2000330957 creator A5033254089 @default.
• W2000330957 creator A5038131926 @default.
• W2000330957 creator A5041568364 @default.
• W2000330957 creator A5044929990 @default.
• W2000330957 creator A5046729324 @default.
• W2000330957 creator A5062197116 @default.
• W2000330957 creator A5062199226 @default.
• W2000330957 creator A5064090610 @default.
• W2000330957 creator A5070712346 @default.
• W2000330957 date "2005-06-01" @default.
• W2000330957 modified "2023-10-17" @default.
• W2000330957 title "Randomised phase II evaluation of irinotecan plus high-dose 5-fluorouracil and leucovorin (ILF) vs 5-fluorouracil, leucovorin, and etoposide (ELF) in untreated metastatic gastric cancer" @default.
• W2000330957 cites W1777256341 @default.
• W2000330957 cites W1848862702 @default.
• W2000330957 cites W1976651872 @default.
• W2000330957 cites W1981480220 @default.
• W2000330957 cites W1985710594 @default.
• W2000330957 cites W1992408996 @default.
• W2000330957 cites W1993341852 @default.
• W2000330957 cites W200233776 @default.
• W2000330957 cites W2012792853 @default.
• W2000330957 cites W201458761 @default.
• W2000330957 cites W2056634859 @default.
• W2000330957 cites W2088650389 @default.
• W2000330957 cites W2095256813 @default.
• W2000330957 cites W2096139576 @default.
• W2000330957 cites W2118247947 @default.
• W2000330957 cites W2119071284 @default.
• W2000330957 cites W2121191168 @default.
• W2000330957 cites W2127191258 @default.
• W2000330957 cites W2128447158 @default.
• W2000330957 cites W2129298161 @default.
• W2000330957 cites W2130522735 @default.
• W2000330957 cites W2139248078 @default.
• W2000330957 cites W2172761866 @default.
• W2000330957 cites W2279052620 @default.
• W2000330957 cites W2314927739 @default.
• W2000330957 cites W2917106067 @default.
• W2000330957 cites W4211113621 @default.
• W2000330957 doi "https://doi.org/10.1038/sj.bjc.6602649" @default.
• W2000330957 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/2361806" @default.
• W2000330957 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/15942629" @default.
• W2000330957 hasPublicationYear "2005" @default.
• W2000330957 type Work @default.
• W2000330957 sameAs 2000330957 @default.
• W2000330957 citedByCount "82" @default.
• W2000330957 countsByYear W20003309572012 @default.
• W2000330957 countsByYear W20003309572013 @default.
• W2000330957 countsByYear W20003309572014 @default.
• W2000330957 countsByYear W20003309572015 @default.
• W2000330957 countsByYear W20003309572016 @default.
• W2000330957 countsByYear W20003309572017 @default.
• W2000330957 countsByYear W20003309572018 @default.
• W2000330957 countsByYear W20003309572019 @default.
• W2000330957 countsByYear W20003309572021 @default.
• W2000330957 countsByYear W20003309572022 @default.
• W2000330957 crossrefType "journal-article" @default.
• W2000330957 hasAuthorship W2000330957A5004381584 @default.
• W2000330957 hasAuthorship W2000330957A5009529288 @default.
• W2000330957 hasAuthorship W2000330957A5013949384 @default.
• W2000330957 hasAuthorship W2000330957A5033254089 @default.
• W2000330957 hasAuthorship W2000330957A5038131926 @default.
• W2000330957 hasAuthorship W2000330957A5041568364 @default.
• W2000330957 hasAuthorship W2000330957A5044929990 @default.
• W2000330957 hasAuthorship W2000330957A5046729324 @default.
• W2000330957 hasAuthorship W2000330957A5062197116 @default.
• W2000330957 hasAuthorship W2000330957A5062199226 @default.
• W2000330957 hasAuthorship W2000330957A5064090610 @default.
• W2000330957 hasAuthorship W2000330957A5070712346 @default.
• W2000330957 hasBestOaLocation W20003309571 @default.
• W2000330957 hasConcept C121608353 @default.
• W2000330957 hasConcept C126322002 @default.
• W2000330957 hasConcept C141071460 @default.
• W2000330957 hasConcept C197934379 @default.
• W2000330957 hasConcept C2776694085 @default.
• W2000330957 hasConcept C2777063308 @default.
• W2000330957 hasConcept C2778119113 @default.
• W2000330957 hasConcept C2778375690 @default.
• W2000330957 hasConcept C2780259306 @default.
• W2000330957 hasConcept C2780456651 @default.
• W2000330957 hasConcept C31760486 @default.
• W2000330957 hasConcept C526805850 @default.
• W2000330957 hasConcept C71924100 @default.
• W2000330957 hasConcept C90924648 @default.
• W2000330957 hasConceptScore W2000330957C121608353 @default.
• W2000330957 hasConceptScore W2000330957C126322002 @default.
• W2000330957 hasConceptScore W2000330957C141071460 @default.
• W2000330957 hasConceptScore W2000330957C197934379 @default.
• W2000330957 hasConceptScore W2000330957C2776694085 @default.
• W2000330957 hasConceptScore W2000330957C2777063308 @default.
• W2000330957 hasConceptScore W2000330957C2778119113 @default.
• W2000330957 hasConceptScore W2000330957C2778375690 @default.
• W2000330957 hasConceptScore W2000330957C2780259306 @default.

• next